Vortioxetine is a unique antidepressant that modulates serotonin receptors alongside standard reuptake inhibition

Health · Published 3 October 2026 Swipe more like this →

In short: Approved in 2013, vortioxetine is a multimodal antidepressant used for major depressive disorder. Unlike traditional SSRIs, it acts as both a serotonin reuptake inhibitor and a modulator of specific serotonin receptors. While its exact clinical mechanism remains debated, it is being studied for potential applications beyond mental health, including cancer therapy.

Vortioxetine, marketed as Trintellix in the United States and Brintellix in Europe, represents a distinct class of medication known as serotonin modulators and stimulators. Its pharmacological profile is complex; it inhibits the serotonin transporter while simultaneously acting as an agonist, partial agonist, or antagonist at various serotonin receptors, including 5-HT1A, 5-HT1B, 5-HT1D, 5-HT3, and 5-HT7. Researchers have noted that its potency for serotonin reuptake inhibition and 5-HT3 receptor antagonism is significantly higher than its activity at other serotonin receptors, though the clinical contribution of these receptor interactions remains a subject of scientific uncertainty.

The drug was developed by Lundbeck and received FDA approval for major depressive disorder in September 2013. While it is often compared to SSRIs, some studies suggest it may cause less emotional blunting and potentially less sexual dysfunction than traditional options, though it still carries risks of nausea and other side effects. Its metabolism is primarily handled by the liver enzyme CYP2D6, which can lead to significant drug-drug interactions; for instance, strong inhibitors like bupropion can more than double vortioxetine levels, necessitating dosage adjustments.

Beyond psychiatry, emerging research explores vortioxetine's potential in other fields. A recent study in pancreatic cancer models found that the drug could enhance the efficacy of the chemotherapy agent gemcitabine by reducing the expression of monoamine oxidase B (MAOB). Additionally, research in mice has linked its antidepressant effects to the normalization of hippocampal SIK2/CRTC1 signaling pathways. While these findings offer intriguing insights into its molecular versatility, the clinical role of vortioxetine continues to evolve as researchers investigate its efficacy for conditions ranging from binge-eating disorder to cognitive enhancement.

General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.

Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?

Related

• Fluoxetine: How a common antidepressant works and why its clinical history is being re-examined.
• How a common antidepressant works to balance brain chemistry and manage complex mental conditions
• Venlafaxine is a potent antidepressant, but its short half-life demands strict daily adherence.
• How SNRIs balance brain chemistry to treat depression and chronic physical pain
• A hugely popular antidepressant whose measured benefit looks surprisingly small
• Somerset Maugham was born inside the British embassy to dodge French conscription
• A pronghorn antelope may use oxygen three times faster than the fittest human
• Water is among the least toxic substances, yet too much too fast can kill
• Thirteen vitamins—named from a wrong "vital amine"
• Calorie deficit shrinks mass—regaining it is the norm
• Four in five cases of vision loss can still be treated
• Most West Nile infections never announce themselves

More in Health, medicine and disease · More in Health · Latest · A–Z · All topics